# US 2025/0082574 A1 · Injectable compositions of triterpenoid antifungals encapsulated in liposomes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082574 A1
- Document ID: US20250082574A1
- Status: Published application
- Kind: A1
- Application number: 18/608,350
- Filed: 2024-03-18
- Published: 2025-03-13
- Earliest claimed: 2018-01-02
- Assignees: Scynexis, Inc.
- Applicants: Scynexis, Inc.
- Inventors: Rajeshwar Motheram
- Web page: https://patentgrep.com/patent/US20250082574A1

## CPC

- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/1277: Preparation processes; Proliposomes
- A61K 31/4196: 1,2,4-Triazoles
- A61K 31/7056: containing five-membered rings with nitrogen as a ring hetero atom
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Injectable compositions of single bilayer vesicles encapsulating enfumafungin derived triterpenoid antifungal compounds can be administered intravenously to treat or prevent fungal infections, while having reduced local injection site reactions (ISRs). The enfumafungin derived triterpenoid antifungal compounds are inhibitors of (1,3)-β-D-glucan synthesis and are useful in the treatment or prevention of fungal infections, such as systemic fungal infections, including those caused by Candida and Aspergillus species.

## Claims

### Claim 1

An injectable composition comprising:
an aqueous phase; and
one or more unilamellar vesicles that each comprise phospholipid and cholesterol, and that each encapsulate a compound of Formula (IIa):
which is (1S,4aR,6aS,7R,8R,10aR,10bR,12aR,14R,15R)-15-[[(2R)-2-amino-2,3,3-trimethylbutyl]oxy]-8-[(1R)-1,2- dimethylpropyl]-14-[5-(4-pyridinyl)-1H-1,2,4-triazol-1-yl]-1,6,6a, 7,8,9,10,10a,10b,11,12,12a-dodecahydro-1,6a,8,10a-tetramethyl-4H-1,4a-propano-2H-phenanthro[1,2-c]pyran-7-carboxylic acid,
or a pharmaceutically acceptable salt or hydrate thereof,
wherein the one or more unilamellar vesicles are hydrated in the aqueous phase.

### Claim 2 (depends on 1)

The injectable composition according to claim 1, wherein the concentration of the encapsulated compound of Formula (IIa) or a pharmaceutically acceptable salt or hydrate thereof in the injectable composition is from about 0.01 to about 50 mg/mL.

### Claim 3 (depends on 1)

The injectable composition according to claim 1, wherein the aqueous phase comprises sugar.

### Claim 4 (depends on 3)

The injectable composition according to claim 3, wherein the pH of the aqueous phase is in the range of from about 5.0 to about 7.0.

### Claim 5 (depends on 1)

The injectable composition according to claim 1, wherein the one or more unilamellar vesicles comprise phosphatidylcholine, phosphatidic acid, phosphatidylserine, phosphatidylethanolamine, phosphatidylglycerol, or combinations thereof.

### Claim 6 (depends on 1)

The injectable composition according to claim 1, wherein the one or more unilamellar vesicles comprise phosphatidylcholine and phosphatidylglycerol.

### Claim 7 (depends on 1)

The injectable composition according to claim 1, wherein the compound of Formula (IIa) or a pharmaceutically acceptable salt or hydrate thereof is present in the vesicles in an amount of about 5 to about 12 mole percent, the phospholipid is present in the vesicles in an amount of about 50 to about 80 mole percent, and the cholesterol is present in the vesicles in an amount of about 10 to about 30 mole percent.

### Claim 8 (depends on 1)

The injectable composition according to claim 1, wherein the phospholipid comprises phosphatidylglycerol and phosphatidylcholine, and the molar ratio of: the compound of Formula (IIa) or a pharmaceutically acceptable salt or hydrate thereof, to the phosphatidylglycerol, to the phosphatidylcholine, to the cholesterol, is 1:2:5:2.5.

### Claim 9 (depends on 1)

The injectable composition according to claim 1, wherein the average particle size of the one or more unilamellar vesicles is less than about 150 nm.

### Claim 10 (depends on 1)

The injectable composition according to claim 1, wherein the average particle size of the one or more unilamellar vesicles is less than about 100 nm.

### Claim 11 (depends on 1)

The injectable composition according to claim 1, wherein the average particle size of the one or more unilamellar vesicles is from about 70 to about 80 nm.

### Claim 12 (depends on 1)

The injectable composition according to claim 1, wherein the one or more unilamellar vesicles encapsulate the compound of Formula (IIa).

### Claim 13 (depends on 1)

The injectable composition according to claim 1, wherein the one or more unilamellar vesicles encapsulate a pharmaceutically acceptable salt of the compound of Formula (IIa).

### Claim 14 (depends on 1)

The injectable composition according to claim 1, wherein the one or more unilamellar vesicles encapsulate the citrate salt of the compound of Formula (IIa).

### Claim 15 (depends on 1)

The injectable composition according to claim 1, wherein the concentration of the encapsulated compound of Formula (IIa) or a pharmaceutically acceptable salt or hydrate thereof in the injectable composition is from about 0.01 to about 50 mg/mL,
wherein the phospholipid comprises phosphatidylglycerol and phosphatidylcholine,
wherein the molar ratio of: the compound of Formula (IIa) or a pharmaceutically acceptable salt or hydrate thereof, to the phosphatidylglycerol, to the phosphatidylcholine, to the cholesterol, is 1:2:5:2.5, and
wherein the aqueous phase comprises sugar and has a pH of from about 5.0 to about 7.0.

### Claim 16 (depends on 1)

A method of treating a fungal infection in a subject in need thereof, the method comprising intravenously administering to the subject the injectable composition according to claim 1.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the subject is a human.

### Claim 18 (depends on 16)

The method according to claim 16, wherein the fungal infection is caused by Candida spp.

### Claim 19 (depends on 16)

The method according to claim 16, wherein the fungal infection is caused by Aspergillus spp.

### Claim 20 (depends on 18)

The method according to claim 18, wherein the fungal infection is candidemia.

### Claim 21 (depends on 19)

The method according to claim 19, wherein the fungal infection is invasive aspergillosis.

### Claim 22

A method of making an injectable composition comprising one or more unilamellar vesicles that each encapsulate a compound of Formula (IIa)
which is (1S,4aR,6aS,7R,8R,10aR,10bR,12aR,14R,15R)-15-[[(2R)-2-amino-2,3,3-trimethylbutyl]oxy]-8-[(1R)-1,2- dimethylpropyl]-14-[5-(4-pyridinyl)-1H-1,2,4-triazol-1-yl]-1,6,a,7,8,9,10,10a,10b,11,12,12a-dodecahydro-1,6a,8,10a-tetramethyl-4H-1,4a- propano-2H-phenanthro[1,2-c]pyran-7-carboxylic acid,
or a pharmaceutically acceptable salt or hydrate thereof,
the method comprising:
a) dissolving phospholipid and cholesterol in an aliphatic alcohol having one to five carbon atoms to form a first solution;
b) dissolving the compound of Formula (IIa) or a pharmaceutically acceptable salt or hydrate thereof in the first solution to form a second solution;
c) mixing the second solution;
d) evaporating the solvent from the second solution to produce a phospholipid-cholesterol dispersion containing the compound of Formula (IIa) or a pharmaceutically acceptable salt or hydrate thereof;
e) hydrating the phospholipid-cholesterol dispersion containing the compound of Formula (IIa) or a pharmaceutically acceptable salt or hydrate thereof with a sugar solution to produce a hydrated suspension; and
f) forming, from the hydrated suspension, one or more unilamellar vesicles that each comprise phospholipid and cholesterol and that encapsulate the compound of Formula (IIa) or a pharmaceutically acceptable salt or hydrate thereof.

### Claim 23 (depends on 22)

The method according to claim 22, wherein the aliphatic alcohol is selected from methanol or ethanol.

### Claim 24 (depends on 22)

The method according to claim 22, wherein the sugar solution comprises sugar selected from monosaccharides, disaccharides, and combinations thereof.

### Claim 25 (depends on 22)

The method according to claim 22, wherein about 90% or more of the amount of the compound of Formula (IIa) or a pharmaceutically acceptable salt or hydrate thereof present during step (b) is encapsulated during step (f) in the one or more unilamellar vesicles.

### Claim 26 (depends on 22)

The method according to claim 22, wherein about 95% or more of the amount of the compound of Formula (IIa) or a pharmaceutically acceptable salt or hydrate thereof present during step (b) is encapsulated during step (f) in the one or more unilamellar vesicles.

### Claim 27 (depends on 22)

The method according to claim 22, wherein during step (f), sonication, microfluidic mixing, homogenization, or a combination thereof is used to form the one or more unilamellar vesicles.

### Claim 28 (depends on 22)

The method according to claim 22, further comprising sterilizing the one or more unilamellar vesicles produced in step (f).

### Claim 29 (depends on 22)

The method according to claim 22, further comprising lyophilizing the one or more unilamellar vesicles produced in step (f).
